In addition, endostatin treatment in patients with nasopharyngeal carcinoma was associated with a lower incidence of nasopharyngeal mucosal necrosis/infection [76], but also with a marked reduction in the frequency and severity of long-term sequelae associated with radiotherapy, such as xerostomia, mouth-opening difficulty, and soft tissue fibrosis [79]. Here, COL18A1 is linked to nasopharyngeal carcinoma.